TNFRSF18 and neoplasm: GITR-specific agonistic mAbs or recombinant GITR ligand (GITRL) fusionproteins have been shown to induce tumor regression in vivo through theactivation of CD4+ T cells, CD8+ T cells and NK cells in severaltumor models [23-25].